Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 8/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538259 | 1.00 | DDB1 (0.43) | DDB1CRBNCDK9CCNT1GRM5 | |
| SCHEMBL28995484 | 0.89 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL23539369 | 0.87 | CRBN (0.50) | DDB1CRBNCDK9GRM5GRM1 | |
| SCHEMBL24881548 | 0.86 | DDB1 (0.45) | DDB1CRBNCDK9CCNT1GRM5 | |
| SCHEMBL31612897 | 0.85 | DDB1 (0.36) | DDB1CRBNCDK9GRM5GRM1 | |
| Bicarbonate SCHEMBL29947119 | 0.84 | CRBN (0.47) | DDB1CRBN | |
| SCHEMBL27367532 | 0.80 | DDB1 (0.44) | DDB1CRBNJAK1 | |
| SCHEMBL23538512 | 0.80 | DDB1 (0.48) | DDB1CRBN | |
| SCHEMBL29090728 | 0.80 | CDK9 (0.30) | CDK9 | |
| SCHEMBL31612916 | 0.80 | DDB1 (0.43) | DDB1CRBNCDK9TNFJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| CN-120118067-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885CDK9 774/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 823/4885CRBN 25/4885CDK9 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.